Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

8209 Background: Of the available 5-HT3-receptor antagonists (RAs), dolasetron, tropisetron and palonosetron include cardiovascular (CV) warnings/precautions in their labelling that should be considered when using these products in patients with existing or possible cardiac impairment. A recent report reviewed CV safety among 5-HT3-RAs and suggested that ECG alteration is a class effect.(1) In contrast, other recently published reports demonstrate important differences regarding CV safety. METHODS: This review will readdress issues regarding CV safety among 5-HT3-RAs. RESULTS: Clinical trials demonstrate that dolasetron is associated with increases in PR, QRS and QTc intervals and increased heart rate, whereas granisetron and ondansetron lack proarrhythmic activity.(2) Recently, a 'signal' for ventricular arrhythmia and cardiac arrest was found for dolasetron but not granisetron in the FDA combined SRS/AERS database (adverse events 1966-present).(3) Granisetron is not associated with significant CV changes, even at doses as high as 160 μg/kg.(4) Ondansetron does not have a CV precaution, but a significant increase in QTc interval has been reported with higher doses.(5) Contrary to the idea that all 5-HT3-RAs carry a similar CV risk, evidence in patients and healthy volunteers suggests otherwise.(3) However, whether trials have reported asymptomatic or clinically relevant 5-HT3-RA-evoked CV changes may be of little relevance, as the issue of CV safety should be considered in context: elderly patients represent the majority of cancer patients and CV comorbidity is common in this population. CONCLUSIONS: QT interval changes have been linked with sudden cardiac death. Thus the CV safety of cancer and supportive therapies, and their additive complications, should be a consideration when choosing therapy. Therefore, it seems prudent to use a 5-HT3-RA that has no warning/precaution concerning CV safety. 1 Navari, Koeller. Ann Pharmacother 2003;37:1276-86 2 Keefe. Oncologist 2002;7:65-72 3 Schnell, Coop. SIOG 2003;37 4 Carmichael, Harris. Anti-Cancer Drugs 2003;14:739-44 5 Boike et al. Am J Health-Syst Pharm 1997;54:1172-6 # [Table: see text].

Type

Journal article

Journal

J Clin Oncol

Publication Date

15/07/2004

Volume

22